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Heparan sulfate serves as a receptor for several herpesviruses. For herpes simplex virus 1 (HSV-1), pseudorabies virus,
and bovine herpesvirus 1, glycoprotein C homologues have been shown to mediate the binding to cell-surface heparan
sulfate. It has been assumed that glycoprotein C of HSV-2 (gC-2) plays a similar role in HSV-2 entry, but this has not been
established experimentally. We first determined, using heparin-affinity chromatography, that gC-2 is a heparin-binding
glycoprotein. To examine the role of gC-2 in HSV-2 infection, we constructed a gC-2 deletion mutant, HSV-2(G)gC0. In
contrast to results obtained for the other a herpesviruses, we found that the HSV-2(G)gC0 virus showed no loss in specific
binding activity (particles bound/cell) or specific infectivity (PFU/particle) compared to the parental wild-type virus. Moreover,
while gC-1 mutants show a marked lag in the rate of viral penetration, the gC-2-deletion virus did not. We did find that gC-
2, like gC-1, protects virus from complement-mediated neutralization. These results suggest that, in contrast to HSV-1, gC-
2 does not play the key role in viral binding. The major role of gC-2 may be to protect virus from complement-mediated
neutralization. We speculate that serotype differences in the contribution of gC to viral binding may contribute to serotype
differences in cell tropism. q 1995 Academic Press, Inc.
INTRODUCTION the genes for HSV-1 gC (gC-1), PrV gC (gIII), or BHV-1
gC (gIII) results in mutants that are impaired in ability to
Entry of alphaherpesviruses into cells requires binding
bind to cells (Herold et al., 1991; Liang et al., 1991;
of virus to receptors on the cell surface which is followed
Schreurs et al., 1988). Moreover, HSV-1, PrV, and BHV-1
by fusion of the virion envelope with the cell plasma
gC can all bind to heparin-affinity columns in physiologi-membrane. This process is complex and may involve
cal saline (Herold et al., 1991; Mettenleiter et al., 1990;multiple interactions between viral glycoproteins and cell
Okazaki et al., 1991) and neutralizing antibodies specificsurface components (Haywood, 1994; Spear, 1993). Re-
for the gC homologues can block the binding of viruscent studies have begun to elucidate the viral and cellular
to cells (Okazaki et al., 1991; Svennerholm et al., 1991;requirements for entry. For herpes simplex virus type 1
Zuckermann et al., 1989).(HSV-1), herpes simplex virus type 2 (HSV-2), pseudora-
Although gC plays the predominant role in viral bind-bies virus (PrV), and bovine herpesvirus type 1 (BHV-1),
ing, mutants devoid of gC are still infectious, but exhibitthe initial interaction of virus with cells is binding of virus
decreased levels of binding and infectivity compared withto cell-surface heparan sulfate. The evidence includes
wild-type virus (Herold et al., 1991; Spear, 1993). Thethe following: (i) Cells devoid of heparan sulfate (but not
requirements for binding of gC-negative virions to cellsother glycosaminoglycans) either due to enzymatic treat-
appears to differ for these three viruses. For HSV-1, an-ment or genetic mutation have greatly reduced numbers
other heparin-binding glycoprotein, gB, mediates the ini-of receptors for viral binding (Gruenheid et al., 1993; Her-
tial binding of gC-negative virions to heparan sulfateold et al., 1994; Mettenleiter et al., 1990; Okazaki et al.,
(Herold et al., 1994). In contrast, for PrV, the binding of gC-1986; Shieh et al., 1992; WuDunn and Spear, 1989) and (ii)
negative virus to cells is not dependent on cell-surfaceheparin, which is structurally similar to heparan sulfate,
heparan sulfate and is not inhibited by heparin (Metten-inhibits the binding of the viruses to cells (Mettenleiter
leiter et al., 1990; Sawitsky et al., 1990). It is not yet knownet al., 1990; Okazaki et al., 1991; WuDunn and Spear,
whether the binding of gC-negative BHV-1 virions to cell1989). For HSV-1, PrV, and BHV-1, a member of the glyco-
requires cell surface heparan sulfate. However, recentprotein C (gC) family plays the predominant role in medi-
studies suggest that binding of gC-negative BHV-1 viri-ating the binding to cell-surface heparan sulfate. This
ons is inhibited by heparin and BHV-1 gB also has affinityconclusion is based on the observations that deletion of
for heparin (Okazaki et al., 1991; Byrne et al., 1995).
For all three viruses, studies suggest that gD may also1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (312) 702-1196. participate in viral binding (Fuller et al., 1987; Highlander
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et al., 1988; Karger et al., 1993; Liang et al., 1991). It has dominant role in HSV-2 binding, but may be important in
protecting HSV-2 from the host immune system.been proposed that gD interacts with a cellular protein
receptor after the initial binding of virus to heparan sul-
fate and that this interaction is required for penetration MATERIALS AND METHODS
(Brunetti et al., 1994; Johnson et al., 1990; Johnson and
Cells and virusesLigas, 1988). Mannose 6-phosphate receptor protein may
serve as one such cellular receptor for gD on select cell HEp-2 cells and Vero cells were obtained from the
types (Brunetti et al., 1994, 1995). American Type Culture Collection. The HEp-2 cells were
For HSV-2, the contribution of individual glycoproteins passaged in Dulbecco’s modified Eagle’s medium sup-
to viral binding has not been experimentally determined. plemented with 10% fetal bovine serum; the Vero cells
It has been assumed that the HSV-2 form of gC (gC-2) were passaged in Medium 199 supplemented with 5%
performs functions in binding similar to the role of the bovine serum. Viral strains used were HSV-2(G) (provided
gC homologues of HSV-1, PrV, and BHV-1. However, al- by B. Roizman, University of Chicago), HSV-1(KOS) (pro-
though both HSV-1 and HSV-2 bind heparan sulfate, the vided by P. Schaffer, Harvard Medical School), and HSV-
two serotypes exhibit differences in epidemiology, cell 1(KOS)DgC2-3 (provided by C. Brandt, University of Wis-
tropism, and susceptibility to inhibitors of viral binding consin). The mutant HSV-1(KOS)DgC2-3 is a gC-1 dele-
that may reflect differences in viral entry. For example, tion virus that was previously described (Herold et al.,
HSV-1 is more likely to cause oral lesions and sporadic 1994). Construction of a gC-2-deletion virus, HSV-
encephalitis, whereas HSV-2 commonly causes genital 2(G)gC0 is described below. All four viruses were propa-
lesions. This epidemiologic observation is supported by gated on HEp-2 cells.
in vitro studies which showed that HSV-1 binds to human
synaptosomes and glial cells more efficiently than HSV- Plasmids and bacteria
2, whereas HSV-2 binds HeLa cells (a cervical cell line)
The plasmid pMN44 (provided by M. Novotny and P.more efficiently than HSV-1 (Vahlne et al., 1979, 1980).
Spear, Northwestern University) served as the sourceIn addition, neomycin, poly-L-lysine, and platelet factor 4
of the Escherichia coli lacZ gene. The plasmid pGEM3inhibit binding of HSV-1, but not HSV-2 (Campadelli-Fi-
(Promega), containing an ampicillin-resistance gene,ume et al., 1990; Langeland et al., 1987, 1988, 1990; Oyan
was used as a template for cloning. The plasmid KZ802et al., 1993). For neomycin, this differential effect on viral
(gift of P. Spear), which contains the gC-2 gene, wasbinding is explained in part by the ability of neomycin
used as a probe for Southern blot analysis. Isolation andto specifically compete with gC-1 for heparan sulfate
purification of plasmid DNA were performed using thereceptors (Herold et al., 1994). The observations that he-
alkaline lysis method (Maniatis et al., 1989). All recombi-paran sulfate is the initial receptor for both HSV-1 and
nant plasmids were produced in E. coli strain JM109. AllHSV-2, but that different cells preferentially bind one ser-
enzymes for cloning were obtained from New Englandotype more than the other and that select inhibitors of
Biolabs and were used according to the specificationsviral binding show serotype-specificity are not necessar-
of the manufacturers.ily contradictory. Rather, these results could be explained
if the relative contributions of individual glycoproteins to Construction and isolation of a gC-2-negative mutant
viral binding are different and/or individual glycoproteins
recognize different structural features of heparan sulfate. Briefly, pGEM3 was modified by insertion of a Bgl II
and an Nco site to facilitate subsequent cloning. A 3.9-The studies in this article were designed to test the
notion that the role of individual glycoproteins in viral kb fragment containing the lacZ gene from pMN44 was
cloned into the modified pGEM3. Subsequently, the lacZbinding may be different for HSV-2 compared to HSV-1.
We focused on gC-2 because gC homologues have been gene was flanked by a 600-bp fragment encoding a se-
quence upstream of the gC-2 gene (cloned into the plas-shown to play the predominant role in binding for the
other a herpesviruses that bind heparan sulfate. We mid between the Bgl II and Nco sites) and a 900-bp frag-
ment encoding a sequence immediately downstream offound, as expected, that gC-2 binds to heparin-affinity
columns under physiologic conditions. However, in con- the gC-2 gene (by blunt-end ligation). The fragments en-
coding sequences upstream and downstream of gC-2trast to the results obtained with gC-deletion mutants for
HSV-1, PrV, and BHV-1, a gC-2 deletion virus did not were amplified using polymerase chain reaction (PCR)
(see below). This final plasmid construct, pBH5, wasshow any impairment in specific binding activity or spe-
cific infectivity. Similar to results of studies with HSV-1 used for cotransfections with HSV-2(G) DNA. Transfec-
tions were performed using the lipofectACE reagent(Friedman et al., 1984; Fries et al., 1986; Harris et al.,
1990; Hidaka et al., 1991; McNearny et al., 1987), we did (Gibco). Recombinant plaques were screened for lacZ
expression and for the absence of expression of gC-find that the presence of gC-2 in the virion envelope
protects virus from complement-mediated neutralization. 2 by an immunoassay using a cocktail of monoclonal
antibodies directed against gC-2 (188-4 and 211, gifts ofThese results suggest that gC-2 does not play the pre-
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P. Spear) (Herold et al., 1994; Holland et al., 1983). One Sepharose beads (Sigma) that had been equilibrated
with PBS containing 0.5% Nonidet P-40 and 0.5% sodiumsuch recombinant, HSV-2(G)gC0, was selected for three
rounds of plaque purification. The viral genome was ana- deoxycholate (PBS–NP40–DOC). The column was
washed with 10 ml of PBS–NP40–DOC (in 2-ml fractions)lyzed by restriction endonuclease digestion and electro-
phoresis or by Southern blot analysis as previously de- and the bound glycoproteins were eluted with 10 ml of
heparin at a concentration of 5–10 mg/ml (in 2-ml frac-scribed (Herold et al., 1994). The phenotype was con-
firmed by Western blot analysis using a polyclonal rabbit tions). In pilot experiments we determined that most of
the viral glycoproteins that flow through the column areantiserum to gC which recognizes both gC-1 and gC-2
(R77, gift of P. Spear) (Towbin et al., 1979). found in the first fraction of the flowthrough and most of
the glycoproteins that bound to the column and were
Polymerase chain reaction eluted with soluble heparin are in the first fraction of the
eluted material. Samples of the starting material, the firstPCR amplification was performed using two sets of
flowthrough fraction, and the first eluted fraction wereprimers which flank the gC-2 gene of HSV-2 (333). The
analyzed by SDS–PAGE and Western blot as previouslyupstream primers were AAAGATCTGGGTTCCCGTGG
described (Herold et al., 1991).and TCCATGGTTTCCCAACCTAACACCCTAAC. The
downstream primers were ATCGTCGGCTGCGGTAACTC PAGE and Western blots
and GAGTTCCGCATGCTTTGTCG. Reaction mixtures
Purified virions were solubilized in SDS sample buffer,contained 500 ng of viral HSV-2(G) DNA, 100 ml of dNTP’s
boiled for 2 min and then loaded onto an 8.5% SDS–(2 mM), 25 pmol of primers, and 7.5 U of Vent DNA
polyacrylamide gel (N,N*-diallyltartardiamide cross-polymerase in standard reaction buffer.
linked). Following SDS–PAGE, the proteins were trans-
Purification and quantification of virus ferred to nylon (Bio-Rad) by Western transfer in 10 mM
Tris, 150 mM glycine, and 20% methanol (Towbin et al.,Virions were radiolabeled with [3H]thymidine and puri-
1979). Western blots were performed as previously de-fied from HEp-2 cells as previously described (Cassai et
scribed. The antisera used were polyclonal rabbit anti-al., 1975; Herold et al., 1991, 1994). For the purified virion
HSV gC (R77), gB (R74), and gD (R72) (obtained frompreparations, titers were determined by plaque assays
P. Spear, Northwestern University) (Herold et al., 1991,on both Vero and HEp-2 cells and radioactivity was deter-
1994).mined by liquid scintillation counting. Virions were quan-
titated by directly counting particles using electron mi- Binding of purified virus to cells
croscopy as previously described (Herold et al., 1991).
Binding studies were performed in duplicate at 47 inAlternatively, the relative number of viral particles was
glass scintillation vials as previously described (Herolddetermined by comparing the relative amounts of the VP5
et al., 1991, 1994; Herold and Spear, 1994). Serial dilu-(major capsid) band by optical densitometry with slight
tions of purified virus of known relative concentrationmodification of previously described methods (Herold et
(VP5 units), specific activity (cpm/VP5 unit), and titer wereal., 1991; Tal-Singer et al., 1995). Several dilutions of sam-
added to HEp-2 cells plated on the bottom of glass scintil-ples of each virion preparation were solubilized, and
lation vials for 5 hr at 47 in triplicate. The viral inoculumpolypeptides were fractionated by sodium dodecyl sul-
was removed and the cells were washed three times atfate (SDS)–polyacrylamide gel electrophoresis (PAGE).
47. The cell-bound radioactivity was then quantitated.Following Coomassie blue staining, gels were scanned
by optical densitometry. Just prior to use for binding stud-
Viral plaque assaysies, purified virus was diluted 1:5 (v/v) in phosphate-buf-
fered saline (PBS; 10 mM Na2HPO4 , 1.5 mM KH2PO4 , 140 Plaque assays were performed in duplicate. HEp-2 or
mM NaCl, 2.5 mM KCl, 0.5 mM MgCl2 , 1 mM CaCl2) and Vero cells in 25-cm2 flasks were inoculated with virus in
centrifuged at 25,000 rpm for 1 hr in a Beckman 70 Ti PBS. After a 2-hr adsorption period at 347, the viral inocu-
rotor to concentrate the virus and remove most of the lum was removed and the cells were overlaid with Me-
dextran. The virus pellet was resuspended in PBS. In- dium 199 supplemented with 1% fetal bovine serum and
fectivity titers and radioactivity were determined for the 0.1% pooled human gamma globulin (199-O). Plaques
resuspended viral pellets. were counted after 2 days of incubation. Vero cells were
fixed and stained with Giemsa to visualize plaques. To
Affinity chromatography visualize HEp-2 cells, an immunoassay was performed
as previously described (Herold et al., 1991).Heparin-affinity chromatography was performed using
extracted viral membrane glycoproteins as previously de-
One-step growth curvescribed (Herold et al., 1991). Membrane proteins were
extracted from 108 PFU of virus and a 200-ml sample of HEp-2 cells were infected at a multiplicity of 5 for 1 hr
at 347. The inoculum was removed and the cells werethe viral extract was applied to a 2-ml column of heparin–
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treated with citrate buffer (40 mM citric acid, 10 mM KCl,
135 mM NaCl [pH 3.0]) for 1 min to inactivate extracellular
virus, washed three times with PBS, and overlaid with
199V. At various time points thereafter, cells were
scraped into the medium, sonicated, and titered.
Assays for rate of virus penetration
The rate of virus penetration was assessed by de-
termining the rate at which adsorbed virus became resis-
tant to inactivation by a low-pH citrate buffer as pre-
viously described (Herold et al., 1991).
FIG. 1. Western blots of extracted membrane proteins from HSV-2(G)Complement neutralization assays
and HSV-2(G)gC0. Membrane proteins were extracted from purified
Neutralization of viral infectivity was assayed as pre- virions (titer 108 PFU/ml) and analyzed by Western blots following
SDS–PAGE. Samples of each virus preparation were run on 8.5% gelsviously described (McNearny et al., 1987). Briefly, in a
and transferred to nylon. For each blot, lane a is HSV-2(G) and lane bvolume of 2.5 ml, the reaction mixtures contained virus
is HSV-2(G)gC0 probed with the respective indicated rabbit polyclonalat 200–1000 PFU/ml and various proportions of human
antisera.
serum or heat-inactivated serum as control (final dilution
of serum 1:10). The diluent for all components of the
reaction was PBS. The human serum chosen for use was umns. The columns were washed with PBS–NP40–DOC
to remove unbound proteins and the bound proteins wereshown to be free of anti-HSV IgG and IgM antibodies by
immunoassays in the virology clinical laboratory at the eluted with buffer containing heparin at 10 mg/ml. Equiv-
alent aliquots of the extracts originally applied to theUniversity of Chicago (FIAX test, BioWhittaker Labora-
tories, for IgG and an immunofluorescence IgM test kit column, the flowthrough fraction, and the heparin-eluted
fraction were analyzed by SDS–PAGE. The gels werefor IgM, Gull Laboratories). Virus and complement were
incubated for 1 hr at 377 and titers were quantified by either silver-stained or transferred to nylon membranes
for Western blot analysis. Results by both silver-stain andplaque assay on HEp-2 cells in duplicate at two different
dilutions. Western blot were similar. A representative Western blot
of starting material, flowthrough, and heparin-eluted ma-
terial probed with polyclonal antisera specific for gC (Fig.RESULTS
2A) or gB (Fig. 2B) is shown. We found that almost all of
Properties of a new gC-negative mutant virus
the gC-2 bound to the heparin–Sepharose column and
of HSV-2(G)
was eluted by soluble heparin. No gC-2 was detected in
the blot from HSV-2(G)gC0 probed with polyclonal anti-A gC-negative mutant, HSV-2(G)gC0 was constructed
from HSV-2(G) as described under Materials and Meth- gC serum (Fig. 1). Figure 2B shows results of blots incu-
bated with antiserum directed against gB. We found thatods. To confirm that HSV-2(G)gC0 contained the lacZ
gene in place of the gC-2 gene, DNA from infected cells almost all of the gB-2 also bound to the heparin–Sepha-
rose column and was eluted by soluble heparin for bothwas digested with Bgl II and EcoRV and analyzed by
Southern blot hybridization using either the plasmid HSV-2(G) and HSV-2(G)gC0 virions. Blots were also
probed for gD-2 which eluted with the flowthrough (datapKZ802 which contains the gC-2 gene or a plasmid that
contains the lacZ gene (pBH5) as probes. The predicted not shown). Thus, an anticipated from studies with HSV-
1, gC-2 and gB-2 are major heparin-binding glycopro-fragments were detected (data not shown). The lack of
gC expression of the mutant was also confirmed by West- teins. The ability of gB-2 to bind to heparin independently
of gC-2 is similar to results obtained for HSV-1 (Heroldern blot. In Fig. 1, a Western blot of membrane proteins
extracted from HSV-2(G) (lane a) or HSV-2(G)gC0 (lane et al., 1991) and BHV (Li et al., 1995), but differs from
results obtained with affinity chromatography for PrV; forb) probed with polyclonal antiserum to gB, gD, or gC as
indicated is shown. Glycoproteins B and D are readily PrV the gB homologue only binds to heparin if the gC
homologue is also present (Mettenleiter et al., 1990).detected both in the wild-type and in the gC-deletion
virus. In contrast, the 70-kDa protein, gC-2, is detected
HSV-2(G)gC0 exhibits normal specific infectivity,only in the lane containing the wild-type virus.
specific binding activity, rates of penetration, and
growth kineticsIdentification of HSV-2 heparin-binding glycoproteins
Envelope proteins were extracted from purified wild- To determine whether gC-2 plays a key role in HSV-2
infection, we first compared the specific infectivity (PFU/type HSV-2(G) and HSV-2(G)gC0 virions with PBS –
NP40–DOC and applied to heparin–Sepharose col- particle) of HSV-2(G) and HSV-2(G)gC0. Purified prepara-
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FIG. 2. Affinity for heparin–Sepharose of envelope glycoproteins ex-
tracted from purified HSV-2(G) or HSV-2(G)gC0. Envelope proteins were
extracted with PBS–NP40–DOC, and the solubilized material was ap-
plied to heparin–Sepharose columns. The columns were washed with
extraction buffer and then eluted with heparin at 10 mg/ml. Samples
representing equivalent fractions of the input (a), flowthrough (b), and
heparin-eluted (c) material were analyzed by SDS–PAGE and Western
blot. Representative blots are shown above. (A) Extracted membrane
FIG. 3. Quantification of relative number of viral particles in a purifiedproteins from HSV-2(G) probed with antiserum specific for gC. (B) Ex-
preparation of HSV-2(G) or HSV-2(G)gC0 using optical densitometry.tracted membrane proteins from HSV-2(G) (left lanes) and HSV-2(G)gC0
Dilutions of proteins solubilized from HSV-2(G) or HSV-2(G)gC0 virions(right lanes) probed with antiserum specific for gB.
were analyzed by scanning a Coomassie blue-stained gel following
SDS–PAGE. Lanes a, b, c represent 100, 50, and 10 ml of HSV-2(G),
respectively; lanes a*, b*, c* represent 100, 50, and 10 ml of HSV-tions of each viral strain were analyzed with respect to
2(G)gC0, respectively. The average relative optical densitometry read-titer of infectious units on HEp-2 cells and virion concen-
ings are shown in Table 1.tration either by counting particles in the electron micro-
scope or by quantitation of relative numbers of virions
scope. As anticipated from results depicted in Table 1,by comparisons of the amounts of VP5 (major capsid
there was no significant difference in specific infectivityprotein) present in each preparation. In previous studies
of HSV-2(G) wild type compared to the gC-2-deletion vi-with HSV-1, we showed that quantitation of relative parti-
rus. In contrast, deletion of gC-1 resulted in a much lowercle numbers by densitometry yielded results similar to
PFU/particle ratio compared to the parental wild-type vi-those obtained by counting particles using electron mi-
rus. These results for HSV-1 are similar to results pre-croscopy (Herold et al., 1991). Subsequently, several in-
viously reported for a different gC-negative mutant, gC03vestigators have utilized densitometry to quantitate rela-
(Herold et al., 1991). This difference in the relative spe-tive particle numbers (Tal-Singer et al., 1995). To test
cific infectivities of a gC-2-deletion virus compared to gC-whether the VP5 units also correlated with particle num-
1-deletion viruses suggests differences in the contribu-bers for HSV-2, we conducted experiments using both
tion of gC to HSV-2 and HSV-1 infectivity.techniques; the results obtained were comparable.
To directly determine the role of gC-2 in viral binding,Figure 3 shows the relative amounts of purified mutant
we next compared the specific binding activity (particlesand wild-type viruses on a representative Coomassie
bound/cell) for the wild-type and gC-deletion virus. Toblue-stained gel for HSV-2(G) and HSV-2(G)gC0. The den-
quantitate the binding of virus to cells without the compli-sitometry values showed a linear relationship with serial
cation of viral entry, the binding studies were performeddilutions of the purified viral preparations. As shown in
Table 1, the densitometry values for each VP5 band show
that there were approximately three times more HSV- TABLE 1
2(G)gC0 than HSV-2(G) viral particles/100 ml for these
Relative Specific Infectivity (PFU/Relative Particle Number)purified viral preparations. However, the relative titer of
of Wild-Type and gC-Negative HSV-2(G) on HEp-2 Cells
the HSV-2(G)gC0 was also approximately three times
greater than the titer of the HSV-2(G) preparation; this Relative
specificresults in a comparable specific infectivity. Similar results
HEp-2 titer infectivitywere obtained from several different preparations of puri-
VP5 (OD) (PFU/ml) (PFU/OD)fied virions. The ratio of the relative particle numbers
obtained for HSV-2(G) compared to HSV-2(G)gC0 ranged HSV-2(G) 1 3 1 107 3.0 1 107
from 1:1 to 1:3; the resulting ratio of specific infectivities HSV-2(G)gC0 2.9 1 1 108 3.4 1 107
calculated for HSV-2(G) compared to HSV-2(G)gC0
Note. Plaque dishes of HEp-2 cells were inoculated with purifiedranged from 1:1.1 to 1:1.8.
wild-type (G) or gC-negative (gC0) virions for 2 hr at 347. Dishes wereTable 2 shows the specific infectivities obtained for
overlaid with Medium 199-O, and plaques were counted after 2 days.
HSV-1(KOS) and HSV-2(G) and their respective gC-dele- The relative concentrations of virions were determined by optical densi-
tion viruses; for these experiments particle numbers tometry of a Coomassie-stained SDS–PAGE gel (shown in Fig. 3) and
are expressed as arbitrary OD units.were determined by direct counting in the electron micro-
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TABLE 2 for HSV-1(KOS)gC-1-mutant viruses. For example, it takes
approximately 40–45 min for 50% of HSV-1(KOS)gC0 viri-Specific Infectivity (PFU/Particle) of Wild-Type HSV-1 (KOS) and
ons to penetrate compared to 10–15 min for HSV-1(KOS),HSV-2(G) Compared with Their Respective gC-Deletion Viruses on
HEp-2 Cells HSV-2(G), and HSV-2(G)gC0 (Herold et al., 1991; and un-
published data). These results further confirm the notion
Wild-type gC-deletion that gC-2 plays a different role than gC-1 in viral entry.
To determine if absence of gC influenced the growthHSV-1(KOS) 0.056 { 0.02 0.001 { 0.0002
kinetics of HSV-2, we compared single-step growthHSV-2(G) 0.05 { 0.02 0.04 { 0.015
curves for HSV-2(G) and the gC-2-deletion virus on HEp-
Note. Purified virions were inoculated onto plaque dishes of human 2 cells. We found that the growth kinetics of the gC-2-
HEp-2 cells for 2 hr at 347. Dishes were overlaid with Medium 199-O, deletion virus were similar to that of the parental wild-
and plaques were counted after 2 days. Particle numbers for each
type HSV-2(G) virus (Fig. 6). Taken together, the resultspreparation of purified virions were determined by electron microscopy
of the binding studies, specific infectivity studies, andas previously described (Herold et al., 1991). Mean values obtained
were 3.6 1 1010 particles/ml for HSV-1(KOS), 1.4 1 1010 particles/ml kinetics of growth and penetration suggest that, although
for HSV-1(KOS)DgC2-3, 9.7 1 109 particles/ml for HSV-2(G), and 1.3 1 gC-2 is a heparin-binding glycoprotein, it does not play
1010 particles/ml for HSV-2(G)gC0. Specific infectivity was calculated the predominant role in HSV-2 binding to HEp-2 or Vero
from an experiment performed in duplicate at two different dilutions
cells.and is presented as mean { standard error. The difference between
HSV-1(KOS) and the gC-1-deletion virus with respect to specific infec-
Glycoprotein C protects HSV-2 from complement-tivity is significant (P  0.001); there is no significant difference with
respect to specific infectivity between HSV-2(G) and the gC-2-deletion mediated neutralization
virus.
Glycoprotein C-1 has also been shown to protect HSV-
1 from complement-mediated neutralization in cell cul-
at 47 as described under Materials and Methods. The ture (Friedman et al., 1984; Fries et al., 1986; Harris et
results of a representative experiment are presented in al., 1990; Hidaka et al., 1991; McNearny et al., 1987). It
Fig. 4. At equivalent concentrations of input virions (over has been presumed that gC-2 also protects HSV-2 from
the range tested), there was no significant difference complement-mediated neutralization, in part because
between the wild-type parental strain (G) and the gC- gC-2 also binds complement (Eisenberg et al., 1987;
deletion mutant in the number of virions bound to HEp- Hung et al., 1994; McNearny et al., 1987; Seidel-Dugan
2 cells. These results contrast sharply with results pre- et al., 1990) and because on an HSV-1 background (MP),
viously obtained for HSV-1 in which the gC-deletion virus the presence of gC-2 in the viral envelope protected
showed reduced specific binding activity and saturated
receptors on HEp-2 cells at an input of 50–100 PFU/cell
(Herold et al., 1991). The specific binding activity of HSV-
2(G)gC0 differs from binding activities observed for HSV-
1, PrV, and BHV-1 gC-deletion mutants; for all three of
those viruses, the gC-deletion virus showed reduced
specific binding activity (Herold et al., 1991, 1994; Metten-
leiter et al., 1990; Okazaki et al., 1991). These results
suggest that although gC is a heparin-binding glycopro-
tein, it does not play the predominant role in binding to
HEp-2 cells.
For HSV-1(KOS), gC-deletion viruses also show a lag
in the rate of penetration both on HEp-2 and on Vero
cells (Herold et al., 1991, 1994). To determine if gC-2
plays a similar role in the rate of penetration for HSV-2,
FIG. 4. Comparison of the binding of HSV-2(G) and HSV-2(G)gC0we compared the rates of penetration of HSV-2(G) and
virions to HEp-2 cells. Serial dilutions of purified virions were addedHSV-2(G)gC0 on both HEp-2 and Vero cells (Herold et
to HEp-2 cells which had been plated on the bottoms of glass scintilla-al., 1991). Virions were adsorbed to cells for 3 hr at 47.
tion vials. Binding was carried out for 5 hr at 47. After washing away
After any unbound virus was washed away, the cells unbound virus, scintillation fluid was added to the vials for quantitation
were incubated at 347 for various times and then exposed of cell-bound radioactivity. The concentrations of input virions were
determined by densitometry of a Coomassie-stained SDS–PAGE gelto a low-pH citrate buffer (or to PBS as a control) to
and are expressed as relative VP5 units and ranged from an input ofinactivate any bound virus that had not yet penetrated
10 to 200 PFU/cell. The bound virus was determined from the knownthe cell. The results presented in Fig. 5 show that there
ratios of radioactivity and VP5 units for each virus preparation. Each
was no delay in the penetration of adsorbed HSV- point represents the average value from duplicate samples, and the
2(G)gC0 virus compared to that of HSV-2(G) on either error bars represent standard deviations. Two independent experi-
ments were performed with comparable results.cell line. These results again differ from results obtained
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FIG. 5. Rates of penetration into Vero cells (left) or HEp-2 cells (right) of HSV-2(G) and HSV-2(G)gC0 virions. Confluent monolayers of cells in 25-
cm2 flasks were inoculated with 1000 PFU of virus for a 3-hr adsorption period at 47. After removal of the unbound virus and thorough washing
of the cells, the flasks were shifted to 347 to allow penetration to proceed. At selected times after the temperature shift, duplicate monolayers were
treated for 1 min with 1 ml of citrate buffer or with PBS. The monolayers were then washed three times and overlaid with 199-O. Plaques were
counted after 2 days. The number of plaques on the control cultures treated with PBS were essentially the same for all time points, and the average
value was taken as 100%. The results are presented as the PFU surviving citrate treatment at each time point expressed as a percentage of the
PBS control value. Each point represents the average of duplicate determinations, and the error bars represent the range of values obtained. Two
independent experiments were performed for each virus on both cell lines with comparable results.
HSV-1(MP) from complement-mediated neutralization even at relatively low concentrations of serum (final con-
centration 3.3% serum, 6.7% HIS). These results clearly(McNearny et al., 1987). To directly test whether gC-2
could protect HSV-2 from complement-mediated neutral- demonstrate that gC-2 and gC-1 have similar effects, at
least in tissue culture, with respect to protecting virusization, neutralization studies were performed. HSV-
1(KOS) and HSV-2(G) and their respective gC-deletion from complement-mediated neutralization.
viruses were incubated with human serum from a sero-
negative individual. Heat-inactivated human serum (HIS) DISCUSSION
served as the control such that the concentrations of
These studies suggest that gC-2 is not principally re-active complement components differed while concen-
sponsible for the binding of wild-type HSV-2 to HEp-2 ortrations of total serum protein remained constant. As
Vero cells. This conclusion is supported by the findingsshown in Fig. 7, human complement neutralized both
that gC-2-negative virions bind to these cells at least asHSV-1 and HSV-2 only if gC was absent from the virion
efficiently as wild-type virions and show no defect inenvelope. Both gC-deletion viruses were neutralized
rates of penetration, growth kinetics, or specific infecti-
FIG. 6. One-step replication kinetics of HSV-2(G) and HSV-2(G)gC0.
HEp-2 cells were infected at a m.o.i. of 5 with the wild-type or gC-2- FIG. 7. Effects of human complement on HSV infectivity. Unheated
(normal human serum) and heated samples of anti-HSV antibody-nega-deletion virus. After 1 hr at 347, extracellular virus was inactivated by
pH 3.0 citrate buffer treatment, and monolayers were overlaid with tive human serum were mixed in the proportions indicated (final dilution
of serum 1:10) with virus at 200–1000 PFU/ml and incubated for 1 hrfresh medium. Immediately afterward (t  0), and at several times
thereafter, supernatants and cell pellets were harvested and titered. at 377; infectious titers were determined on HEp-2 cells. The values
presented are the average of two independent experiments performedEach point represents the average of duplicate determinants and the
error bars represent the range of values obtained. in duplicate and the error bars represent the range of values obtained.
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vity. However, gC-2 is a heparin-binding glycoprotein and Second, the notion that the gC and gB interact with
different structural features of heparan sulfate and thatmay still participate in viral binding, perhaps on other
cell types or under select conditions. Interestingly, the gC plays the predominant role in binding for HSV-1, but
not HSV-2, is further supported by studies with neomycin.results obtained for gC-2 with respect to viral binding
are similar to the results obtained for HSV-1 gB (gB- It had previously been observed that neomycin, a polyca-
tion, inhibited HSV-1 infection to a much greater extent1). Deletion of gB-1 alone also does not result in any
detectable impairment of viral binding. However, gB-1 is than HSV-2 infection (Campadelli-Fiume et al., 1990;
Langeland et al., 1987, 1988, 1990; Oyan et al., 1993). Wealso a heparin-binding glycoprotein and does participate
in viral binding to heparan sulfate, at least when gC-1 is reported that neomycin has two distinct effects on HSV-
1 infection (Herold et al., 1994). First, it inhibits the bind-absent from the virion envelope (Herold et al., 1994).
Affinity chromatography studies suggest that if gC-2 does ing of gC-positive, but not gC-negative, HSV-1 virions to
cells because it competes with gC for heparan sulfatenot play the predominant role in HSV-2 binding, then gB-
2, the other major heparin-binding glycoprotein identified, receptors (Herold et al., 1994). Second, neomycin inhibits
postbinding events independent of the presence of gCmay play the principal role in HSV-2 attachment to cell-
surface heparan sulfate for both the wild-type and the in the virion envelope. The observation here that gC-2
does not play a predominant role in HSV-2 binding maygC-2 deletion virus. Thus, we would predict that wild-
type HSV-2 might resemble HSV-1 gC-1-deletion viruses explain, in part, why neomycin fails to inhibit HSV-2 bind-
ing (Campadelli-Fiume et al., 1990; Langeland et al.,with respect to various aspects of viral binding.
Based on the results obtained in these studies, we 1987, 1988, 1990; Oyan et al., 1993; B. C. Herold, unpub-
lished data).conclude that the relative contributions of gC and gB for
viral attachment for HSV-1 and HSV-2 may be quite differ- The domains of gC and gB necessary for binding to
heparan sulfate have not yet been definitively identified.ent and hypothesize that these differences may help ex-
plain serotype differences in cell tropism. The notion that Using synthetic peptides, Trybala and co-workers
showed that several amino acid residues including Arg-gC and gB might contribute differently to viral attachment
for HSV-1 and HSV-2 is supported by several other lines 143, Arg-145, Arg-147, and Thr-150 may be involved in
the interaction between gC-1 and cell-surface heparanof evidence. First, although both HSV-1 and HSV-2 bind
heparan sulfate, there is evidence that the two serotypes sulfate (Trybala et al., 1994). Relatively high local concen-
trations of basic amino acids are characteristic of thebind with different efficiencies to different cell types
(Vahlne et al., 1979, 1980). This observation could be ex- heparin-binding domains of some proteins (Spear, 1993),
and thus the arginine- and lysine-rich region near the N-plained if HSV-1 and HSV-2 (or the individual glycopro-
teins) bind different specific structural features of heparan terminus of gC and the lysine-rich region near the N-
terminus of gB are good candidates for heparin-bindingsulfate that are differentially expressed on different cell
types. Using a series of modified heparin compounds, we domains. Interestingly, the amino acid sequences of gC
and gB are highly conserved between the two serotypesrecently showed that gC-1 and gB-1 bind different, but
overlapping structural features of heparan sulfate (Herold except at the N-termini and particularly in the basic re-
gions indicated (Dowbenkos and Lasky, 1984; Spear,et al., 1995). For example, we found that a carboxyl-re-
duced modified heparin compound inhibited the binding of 1993; Swain et al., 1985). In particular, the genes for gC-
1 and gC-2 have diverged to a greater extent than mostgC-1-positive viruses [HSV-1(KOS) and HSV-1(KOS)KO82],
but not the binding of gC-1-negative virus [HSV- of the other glycoprotein genes. Thus, the variability in
amino acid sequences supports the notion that the indi-1(KOS)DgC2-3] to cells (Herold et al., 1995). These results
suggest that the carboxyl group is a critical determinant vidual glycoproteins might recognize different structural
features of heparan sulfate and might play different rolesfor interactions of gB-1, but not gC-1, with cell-surface
heparan sulfate. Studies are in progress to compare the in mediating the binding of HSV-1 and HSV-2 to different
cell types.effects of these modified heparin compounds on the bind-
ing of HSV-1 and HSV-2. We predict that modified heparin Not only are there differences between gC-1 and gC-
2 with respect to their role in viral binding, but interestingcompounds that specifically inhibit interactions of gC, but
not gB, with heparan sulfate will have little or no inhibitory differences have been reported with respect to their inter-
actions with complement, at least in vitro. Both gC-1 andeffect on binding of HSV-2; conversely, compounds might
be found that inhibit the binding of HSV-2, but not HSV-1. In gC-2 are capable of binding complement components
C3b and iC3b in vitro (Eisenberg et al., 1987; Fries et al.,preliminary studies we found, as predicted, that carboxyl-
reduced heparin (a compound that specifically inhibits 1986; Harris et al., 1990; Huemer et al., 1992, 1993; Hung
et al., 1994; McNearny et al., 1987; Seidel-Dugan et al.,interactions of gC-1 with heparan sulfate) has little or no
inhibitory effect on the binding of HSV-2 to HEp-2 cells. 1990; Smiley and Friedman, 1985; Tal-Singer et al., 1991).
The more extensive studies done with HSV-1 gC showMoreover, 6-O-desulfated heparin inhibits HSV-2 plaque
formation, but has little effect on HSV-1 (Gerber and Her- that it can bind other forms of C3 (Tal-Singer et al., 1991)
and can accelerate decay of the alternative pathway C3old, manuscript in preparation).
/ m4484$7569 10-23-95 23:02:21 vira AP-Virology
37gC-2 FAILS TO PLAY KEY ROLE IN HSV-2 BINDING
herpes simplex virus entry into cells and cell-to-cell transmission. J.convertase (C3bBb) (Fries et al., 1986; Harris et al., 1990;
Virol. 69, 3517–3528.Huemer et al., 1992), whereas gC-2 stabilizes this en-
Brunetti, C. R., Burke, R. L., Kornfeld, S., Gregory, W., Masiarz, F. R.,
zyme (Harris et al., 1990; Huemer et al., 1992). The C3b- Dingwell, K. S., and Johnson, D. C. (1994). Herpes simplex virus
binding activity of gC-1 is expressed both on virions and glycoprotein D acquires mannose 6-phosphate residues and binds
to mannose 6-phosphate receptors. J. Biol. Chem. 269, 17067–17074.on infected cell surfaces, whereas the C3b-binding activ-
Byrne, K. M., Horohov, D. W., and Kousoulas, K. G. (1995). Glycoproteinity of gC-2 is only detectable on virions (Eisenberg et al.,
B of bovine herpesvirus-1 binds heparin. Virology 209, 230–235.1987). Using a series of constructed mutants of gC-1
Cai, W., Person, S., Warner, S. C., Zhou, J., and DeLuca, N. A. (1987).
and gC-2, the C3b-binding regions have been mapped Linker-insertion nonsense and restriction-site deletion mutations of
to similar portions of each protein (Hung et al., 1994; the gB glycoprotein gene of herpes simplex virus type 1. J. Virol. 61,
714–721.Seidel-Dugan et al., 1990). Previous studies have shown
Cai, W., Gu, B., and Person, S. (1988). Role of glycoprotein B of herpesthat expression of C3b-binding activity (either gC-1 or
simplex virus type 1 in viral entry and cell fusion. J. Virol. 62, 2596–gC-2) protects HSV-1 from complement-mediated lysis
2604.
(Friedman et al., 1984; Hidaka et al., 1991; McNearny et Campadelli-Fiume, G., Stirpe, D., Boscaro, A., Avitabile, E., Tomasi,
al., 1987). The importance of gC in protecting HSV-2 from L., Barker, D., and Roizman, B. (1990). Glycoprotein C-dependent
attachment of herpes simplex virus to susceptible cells leading tocomplement-mediated neutralization had not been di-
productive infection. Virology 178, 213–219.rectly tested. We found that gC-2 also protects HSV-2
Cassai, E. N., Sarmiento, M., and Spear, P. G. (1975). Comparison offrom complement-mediated lysis. Whether this C3b-bind-
the virion proteins specified by herpes simplex virus types 1 and 2.
ing activity contributes to pathogenesis and whether the J. Virol. 16, 1327–1331.
contribution differs for HSV-1 and HSV-2 remains to be Dowbenkos, D. J., and Lasky, L. A. (1984). Extensive homology between
the herpes simplex virus type 2 glycoprotein F gene and the herpesdetermined.
simplex virus type 1 glycoprotein C gene. J. Virol. 52, 154–163.Based on the studies presented here, we conclude
Eisenberg, R. J., Ponce de Leon, M., Friedman, H. M., Fries, L. F.,that gC-1 and gC-2 may play similar roles with respect
Frank, M. M., Hastings, J. C., and Cohen, G. H. (1987). Complement
to protecting HSV-1 and HSV-2 from the host immune component C3b binds directly to purified glycoprotein C of herpes
system. However, the two glycoproteins differ in their simplex virus types 1 and 2. Microb. Pathog. 3, 423–435.
Friedman, H. M., Cohen, G. H., Eisenberg, R. J., Seidel, C. A., and Cines,relative role in viral entry. For HSV-1, but not HSV-2, gC
D. B. (1984). Glycoprotein C of herpes simplex virus 1 acts as aplays the predominant role in binding (at least in vitro),
receptor for the C3b complement component on infected cells. Na-although gC-2 may contribute to the interactions of HSV-
ture 309, 633–635.
2 with cell-surface heparan sulfate. It seems likely that Friedman, H. M., Glorioso, J. C., Cohen, G. H., Hastings, J. C., Harris,
gB-2, the other major heparin-binding glycoprotein, may S. L., and Eisenberg, R. J. (1986). Binding of complement component
C3b to glycoprotein gC of herpes simplex virus type 1: Mapping ofplay the key role in mediating HSV-2 binding. Studies
gC-binding sites and demonstration of conserved C3b binding inare ongoing to generate gB-deletion mutants to directly
low-passage clinical isolates. J. Virol. 60, 470–475.assess the role of gB in binding independent of its role
Fries, L. F., Friedman, H. M., Cohen, G. H., Eisenberg, R. J., Hammer,
in viral penetration. We speculate that differences in the C. H., and Frank, M. M. (1986). Glycoprotein C of herpes simplex
relative contribution of gC and gB to viral binding for virus 1 is an inhibitor of the complement cascade. J. Immunol. 137,
1636–1641.HSV-1 and HSV-2 may help explain differences in tropism
Fuller, A. O., and Spear, P. G. (1987). Anti-glycoprotein D antibodiesand in viral pathogenesis. For example, it may be that
that permit adsorption but block infection by herpes simplex virus 1cells that preferentially bind HSV-1 express more gC-
prevent virion–cell fusion at the cell surface. Proc. Natl. Acad. Sci.
specific structural features of heparan sulfate, whereas USA 84, 5454–5458.
cells that preferentially bind HSV-2 express more gB- Gruenheid, S., Gatzke, L., Meadows, H., and Tufaro, F. (1993). Herpes
specific structural features of heparan sulfate. Identifica- simplex virus infection and propagation in a mouse L mutant lacking
heparan sulfate proteoglycans. J. Virol. 67, 93–100.tion of the specific heparan sulfate sequences that bind
Harris, S. L., Frank, I., Yee, A., Cohen, G. H., Eisenberg, R. J., andindividual glycoproteins will help resolve this complex
Friedman, H. M. (1990). Glycoprotein C of herpes simplex virus typepuzzle. 1 prevents complement-mediated cell lysis and virus neutralization.
J. Infect. Dis. 162, 331–337.ACKNOWLEDGMENTS
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